Cannabinoids and triple-negative breast cancer treatment

Dobovišek, Luka (author), Borštnar, Simona (author), Debeljak, Nataša (author), Kranjc Brezar, Simona (author)

Triple-negative breast cancer (TNBC) accounts for about 10-20% of all breast cancer cases and is associated with an unfavorable prognosis. Until recently, treatment options for TNBC were limited to chemotherapy. A new successful systemic treatment is immunotherapy with immune checkpoint inhibitors, but new tumor-specific biomarkers are needed to improve patient outcomes. Cannabinoids show antitumor activity in most preclinical studies in TNBC models and do not appear to have adverse effects on chemotherapy. Clinical data are needed to evaluate efficacy and safety in humans. Importantly, the endocannabinoid system is linked to the immune system and immunosuppression. Therefore, cannabinoid receptors could be a potential biomarker for immune checkpoint inhibitor therapy or a novel mechanism to reverse resistance to immunotherapy. In this article, we provide an overview of the currently available information on how cannabinoids may influence standard therapy in TNBC.

• Language: English
• Keywords: triple-negative breast cancer, breast cancer, cancer treatment, cannabinoids, endocannabinoid system, chemotherapy, immunotherapy, immune system, tumor microenvironment, immune checkpoint inhibitors
• Work type: Article
• Typology: 1.02 - Review Article
• Organization: MF - Faculty of Medicine
• Publication status: Published
• Publication version: Version of Record
• Year: 2024
• Number of pages: 13 str.
• Numbering: Vol. 15, art. 1386548
• PID: 20.500.12556/RUL-165016
• UDC: 618.1
• ISSN on article: 1664-3224
• DOI: 10.3389/fimmu.2024.1386548
• COBISS.SI-ID: 204044547
• Publication date in RUL: 21.11.2024

Record is a part of a journal

• Title: Frontiers in immunology
• Shortened title: Front. immunol.
• Publisher: Frontiers Media
• ISSN: 1664-3224
• COBISS.SI-ID: 30774233

Licences

• License: CC BY 4.0, Creative Commons Attribution 4.0 International
• Link: http://creativecommons.org/licenses/by/4.0/
• Description: This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Secondary language

• Language: Slovenian
• Keywords: trojno negativni rak dojke, rak dojke, onkološko zdravljenje, kanabinoidi

Projects

• Funder: ARIS - Slovenian Research and Innovation Agency
• Project number: J3-3062
• Name: Avtologni imunohibridomi in napredno zdravljenje trojno negativnega raka dojk stadijev II in III

• Funder: ARIS - Slovenian Research and Innovation Agency
• Project number: P3-0003
• Name: Razvoj in ovrednotenje novih terapij za zdravljenje malignih tumorjev